 Globe and Mail | Isotechnika makes executive changes Globe and Mail “This change is designed to allow Dr. Foster to continue to focus firmly on Phase 3 development activities of the company's leading product candidate, voclosporin, for the prevention of kidney transplant rejection, and to continue licensing opportunity ... |
